Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2021 | $27.00 → $28.00 | Buy | HC Wainwright & Co. |
| 7/21/2021 | $34.00 → $27.00 | Buy | HC Wainwright & Co. |
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. "The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201's pulsatile
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company's Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin,
AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) ("Lumos Pharma" or the "Company"), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the Company has entered into a definitive merger agreement, dated October 22, 2024 (the "Merger Agreement") whereby Double Point Ventures LLC ("DPV") will acquire 100% of Lumos Pharma's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right ("CVR") per share payable on achievement of certain milestones (the "Offer"). Following a thorough review of financing and strategic alternatives, Lumos Pharma's
SC 14D9 - LUMOS PHARMA, INC. (0001126234) (Subject)
10-Q - LUMOS PHARMA, INC. (0001126234) (Filer)
SCHEDULE 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)
AUSTIN, Texas, July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach, M.D., Ph.D., accepted his appointment to the Company's Clinical Scientific Advisory Board (CSAB) effective July 15, 2021. Dr. Bach joins the Company's accomplished advisory board comprised of noted pediatric endocrinologists, Peter Clayton, M.D., Ph.D.; Reiko Horikawa, M.D., Ph.D.; George Werther, M.D., Ph.D.; and Chairman, Ron Rosenfeld, M.D. Dr. Bach is currently the Chief Medical Officer for ShouTi Inc., having recently joined from Ascendis Pharma where he served as Senior Vice President, End
AUSTIN, Texas, April 20, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced several changes to its executive team as the Company celebrates one year since the close of its merger. After a distinguished 40-year career as an accountant and financial executive, including over 15 successful years with the Company and its predecessor, Chief Financial Officer Carl Langren has announced his plans to retire effective as of July 4, 2021. Mr. Langren has served as CFO of the Company since November 2018. After his departure, Mr. Langren will continue to serve as a consultant to Lumos Pharma for a
Data published in the Journal of Endocrine Society and accepted for presentation at ENDO 2021 demonstrate distinct mechanism of action and potential efficacy of LUM-201 in subset of pediatric growth hormone deficiency (PGHD) patientsFinal tranche of $26 million non-dilutive funds from PRV sale received in January 2021 AUSTIN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the year ended December 31, 2020 and provided an update on clinical activities and financial guidance for 2021. “The fourth quarter and full year 2020 were marked by signific
SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13G/A - LUMOS PHARMA, INC. (0001126234) (Subject)
SC 13G - LUMOS PHARMA, INC. (0001126234) (Subject)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
4 - LUMOS PHARMA, INC. (0001126234) (Issuer)
Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency Expects to Initiate Phase 3 Trial in Q2 2025 Company to Host Conference Call Today at 4:30PM ET AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2024 and provided a clinical programs update. "Following our very positive and productive End of Phase 2 Meeting with the FDA, we've made substantial progress finalizing our proposa
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company will host a conference call and webcast at 4:30pm ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks. Conference Call and Webcast Details Date: Thursday, August 1, 2024Time: 4:30pm ETDial-in: 1- 866-652-5200 or 1- 412-317-6060 (International)Conference ID: 10191274 Dial-in registratio
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months Company to Host Conference Call May 15, 2024, at 8:30AM ET AUSTIN, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, today announced the outcome from its End-of-Phase 2 meeting with the FDA, provided a clinical programs update, and reported financial results for the quarter ended March 31
HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $28.00 from $27.00 previously
HC Wainwright & Co. reiterated coverage of Lumos Pharma with a rating of Buy and set a new price target of $27.00 from $34.00 previously
Stifel upgraded Lumos Pharma from Hold to Buy and set a new price target of $24.00 from $4.00 previously
Lumos Pharma (NASDAQ:LUMO) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.18) by 9.32 percent. The company reported quarterly sales of $165.00 thousand which missed the analyst consensus estimate of $302.60 thousand by 45.47 percent. This is a 76.12 percent decrease over sales of $691.00 thousand the same period last year.